Study ID | Sex (M/F) | Age (a) | Course of disease (h) | N (E/C) | Intervention | Duration (days) | Outcomes | ADR/ADE | |
---|---|---|---|---|---|---|---|---|---|
Experimental | Control | ||||||||
Li 1999 [15] | 29/33 | 62.9 ± 7.1 (57 ~ 71) | ≤48 | 31/31 | XST 400 mg + WM | WM (Defibrase et al.) | 14 | Total effective rate, changes in cerebral blood flow and hemorheology | Unclear |
Zhang 2002 [16] | 52/48 | 53.0 (37 ~ 70) | ≤72 | 60/40 | Luotai 400 mg + WM | Xiaoshuanling + WM | 14 | Total effective rate | Unclear |
Yuan 2003 [17] | 37/25 | 42 ~ 79 | ≤72 | 32/30 | XST 20 ml + WM | WM (Piracetam et al.) | 15 | Total effective rate, changes in hemorheology | Unclear |
Li 2003 [18] | 69/27 | 55.8 (42 ~ 71) | ≤72 | 48/48 | XST 400 mg | WM (Dextran 40 + citicoline) | 15 | Total effective rate | Unclear |
Li 2005 [19] | - | 48 ~ 73 | ≤72 | 80/76 | XST 200 mg + WM | WM | 20 | Total effective rate | E 3 |
He 2006 [20] | 48/32 | 59.3 ± 12.1 (46 ~ 80) | ≤72 | 40/40 | XST 10 ml + WM | Dextran 40 + WM | 14 | Total effective rate, neurological deficit score | None |
Wang 2006 [21] | 34/21 | 63.8 (39 ~ 79) | ≤24 | 36/19 | XST 600 mg + WM | Venoruton + WM | 21 | Total effective rate | None |
Yuan 2006 [22] | 64/31 | 63.0 ± 10.4 (46 ~ 74) | ≤24 | 49/46 | XST 250 ~ 500 mg + WM | WM (Defibrase et al.) | 15 | Total effective rate | E 3 |
C 7 | |||||||||
Zhao 2006 [23] | 43/38 | 60.9 ± 8.1 (45 ~ 70) | ≤72 | 40/41 | XST 10 ml + WM | WM (Sodium ozagrel + Defibrase et al.) | 14 | Total effective rate, changes in hemorheology | Unclear |
Li 2007 [24] | 54/36 | 59.5 ± 13.2 (48 ~ 79) | ≤48 | 45/45 | XST 10 ml + WM | Dextran 40 + WM | 15 | Total effective rate | None |
Wang 2007A [25] | 50/26 | 63.6 (39 ~ 82) | ≤24 | 50/26 | XST 600 mg + WM | Venoruton + WM | 21 | Total effective rate | None |
Wang 2007B [26] | - | 69.4 (43 ~ 80) | ≤72 | 30/30 | XST 20 ml + WM | WM (Venoruton et al.) | 14 | Total effective rate | None |
Rong 2008 [27] | 50/46 | 59.1 ± 8.4 (39 ~ 77) | ≤72 | 51/45 | XST 400 mg + WM | Venoruton + WM | 14 | Total effective rate, neurological deficit score, Modified Barthel Index, changes in hemorheology | None |
Zhang 2008 [28] | 70/50 | 56 ± 11 (48 ~ 78) | ≤48 | 65/65 | XST 200 ~ 400 mg + WM | WM | 15 | Total effective rate, changes in hemorheology | Unclear |
Zi 2008 [29] | 49/33 | 59.5 ± 13.2 (48 ~ 79) | ≤48 | 41/41 | XST 10 ml + WM | Dextran 40 + WM | 15 | Total effective rate, neurological deficit score | None |
Duan 2009 [30] | 35/34 | 64.5 ± 8.2 (33 ~ 75) | ≤48 | 36/33 | XST 500 mg + WM | WM | 14 | Total effective rate | None |
Ma 2009 [31] | 117/83 | 65.1 ± 7.0 (45 ~ 85) | ≤72 | 100/100 | XST 400 mg + WM | Venoruton + WM | 15 | Total effective rate, neurological deficit score, changes in hemorheology, glycemia and lipidemia | E 9 |
C 10 | |||||||||
Cai 2011 [32] | 42/18 | 64.2 (47 ~ 86) | ≤48 | 30/30 | XST 400 mg + WM | WM (Buflomedil hydrochloride + Low molecular heparin) | 14 | Total effective rate, neurological deficit score | E 2 |
C 1 | |||||||||
Fu 2011 [33] | 62/58 | 55.4 ± 5.1 | ≤48 | 64/58 | XST 400 mg + WM | WM (Sodium ozagrel et al.) | 14 | Total effective rate, neurological deficit score | None |
He 2011 [34] | 57/65 | 59 ~ 78 | ≤72 | 62/60 | XST 200 mg + WM | WM (Citicoline, Aspirin) | 14 | Total effective rate, neurological deficit score | None |
Wang 2011 [35] | 45/37 | 55.87 ± 5.23 (42 ~ 76) | ≤19 | 41/41 | XST 400 mg + WM | WM | 21 | Total effective rate, Hs-CRP | Unclear |
Yang 2012 [36] | 33/27 | 57 ± 4 (47 ~ 68) | ≤48 | 30/30 | XST 400 mg + WM | WM (Sodium ozagrel et al.) | 14 | Total effective rate | C 2 |
Song 2013 [37] | 117/43 | 62.1 | ≤24 | 80/80 | XST 400 mg + WM | WM | 15 | Total effective rate | Unclear |